Dispute resolution
Goldman Ismail Tomaselli Brennan & Baum LLP
Client satisfactionTarek Ismail, a founding partner at Goldman Ismail Tomaselli Brennan & Baum LLP, stands as a senior leader in Chicago’s commercial disputes space, having successfully led major cases for industry giants such as 3M, GSK, and Bayer. Renowned for his expertise in case strategy, Ismail is involved in a wide range of cases, specialising in product liability litigation and antitrust class actions.
Legal 500 Editorial commentary
- Profile
Accolades
Chicago Elite
Testimonials
Collated independently by Legal 500 research team.
- 'Excellent work product' 'Their team is extraordinary and there are too many amazing lawyers to name them all individually, but Tarek Ismail, Shayna Cook, Joe Tomaselli, Emma Ross, Brian O'Donaghue, Ken Baum, Betsy Farrington, Elizabeth Curtin, and newly added Craig Woods are the smartest, most talented, and hardest working group of people I have ever had the pleasure of working with. Their commitment to achieving the best results for their clients is unwavering, and their level of preparation stands out even among the many other excellent law firms out there.' 'Tarek Ismail, Joe Tomaselli and Ken Baum are the best in the country at what they do. Nobody works harder than them and nobody can rival Tarek in jury trial excellence, or Joe and Ken in their excellence in developing and working with scientific witnesses. They offer tremendous value for the rates they charge, and they work with clients to deliver their excellence within an affordable budget. I simply wouldn't trust any other firm or set of lawyers as much as them with my bet the company litigation.'
Key clients
- Bayer HealthCare Pharmaceuticals Inc.; Bayer HealthCare LLC; Bayer Corp.
- GlaxoSmithKline
- Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Schering-Plough Corp.; Schering Corp.; and MSP Singapore Co. LLC
Work highlights
- Representing Bayer in various Roundup product liability cases, defended Monsanto against allegations that the herbicide caused cancer, achieving a unanimous defense verdict in both Missouri and Philadelphia.
- Representing GSK in Illinois products-liability cases, defending against allegations that Zantac exposed plaintiffs to NDMA, achieving a complete defense victory in May 2024, with a second case voluntarily dismissed during jury selection in June 2024.
- Representing Merck in MDL antitrust actions from the 2010 Zetia Hatch-Waxman patent settlement, with plaintiffs alleging billions in overcharges, led motions to dismiss based on arbitration agreements and prepared for a jury trial that settled in April 2023, while also defending against related opt-out litigation, including a pending motion to dismiss by United HealthCare Services, Inc.